首頁 › 過重 › 明尼蘇達 › Minneapolis
Minneapolis, MN 的 過重 臨床試驗
8 項針對 過重 的研究正在 Minneapolis（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
招募中3 期
- Minneapolis Heart Institute Foundation, Minneapolis
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
招募中3 期
- University of Minnesota, Minneapolis
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
招募中3 期
- International Diabetes Center, Minneapolis
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
招募中3 期
- University of Minnesota Masonic Children's Hospital, Minneapolis
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
招募中3 期
- International Diabetes Center At Park Nicollet, Minneapolis
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
招募中3 期歡迎健康志工
- ACCOMPLISH-2 Research Site, Minneapolis
A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity
招募中4 期
- Clinical Research Institute of Minnesota, Minneapolis
Functional Improvement in OSA and COPD With a Telehealth LifeStyle and Exercise Intervention
招募中
- Minneapolis VA Health Care System, Minneapolis
其他城市的 過重 試驗
- San Antonio, TX34 項研究
- Houston, TX33 項研究
- Chicago, IL29 項研究
- Orlando, FL27 項研究
- Las Vegas, NV23 項研究
- Miami, FL23 項研究
- Dallas, TX20 項研究
- Atlanta, GA20 項研究
- New York City, NY19 項研究
- Jacksonville, FL19 項研究
- Washington, DC19 項研究
- Austin, TX18 項研究
Minneapolis 的其他研究
- 非小細胞肺癌27 項研究
- 乳癌27 項研究
- 卵巢癌24 項研究
- 前列腺癌23 項研究
- 癌症（所有類型）22 項研究
- 心臟衰竭21 項研究
- 急性髓系白血病20 項研究
- 肺癌20 項研究
- 大腸直腸癌19 項研究
- 子宮內膜癌18 項研究
- 帕金森氏症17 項研究
- 心血管疾病15 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。